Metforin, the most commonly prescribed diabetes drug, kills tumor cells that lack key regulatory gene p53, according to a new study by researchers at the University of Pennsylvania School of Medicinr.
More than half of all human cancers have lost the p53 gene. Yet even in an era of molecularly targeted therapies scientists have had trouble figuring out how to compensate for the absence of a gene. Unlike a genetic mutation that changes the function or activity of a gene, which can be inhibited by a well-tailored drug, loss of a gene leaves nothing for the drug to target.
“This is the first time you can show that tumor growth is impaired by a diabetes drug,” says senior author Craig B.